Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Insights - Equillium, Inc. announced the granting of inducement awards consisting of nonstatutory stock options to a new employee, totaling 7,200 shares of common stock, under its 2024 Inducement Plan [1][2] - The stock options have an exercise price of $1.41 per share, which is equivalent to Equillium's closing stock price on October 31, 2025, and will vest over four years [2] Company Overview - Equillium is a biotechnology innovator focused on developing novel therapies for severe autoimmune and inflammatory disorders [3] - The company's lead therapeutic candidate, EQ504, is a potent and selective aryl hydrocarbon receptor (AhR) modulator designed to complement other anti-inflammatory and immunomodulatory agents, with potential applications in treating ulcerative colitis, pouchitis, and pulmonary diseases [3]